The alerting expression of microRNA-411 predicts clinical prognosis and regulates tumor progression of glioblastoma

References

• Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012;14(Suppl 5):v1–49.
   PubMed Web of Science ®Google Scholar
• Kotliarova S, Fine HA. SnapShot: glioblastoma multiforme. Cancer Cell. 2012;21(5):710–710 e1.
   PubMedGoogle Scholar
• Khosla D. Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma. Ann Transl Med. 2016;4(3):54.
   PubMed Web of Science ®Google Scholar
• Cesarini V, Silvestris DA, Tassinari V, et al. ADAR2/miR-589-3p axis controls glioblastoma cell migration/invasion. Nucleic Acids Res. 2018;46(4):2045–2059.
   PubMed Web of Science ®Google Scholar
• Lefranc F, Sadeghi N, Camby I, et al. Present and potential future issues in glioblastoma treatment. Expert Rev Anticancer Ther. 2006 May;6(5):719–732.
   PubMed Web of Science ®Google Scholar
• Liu A, Shen Y, Du Y, et al. Esculin prevents Lipopolysaccharide/D-Galactosamine-induced acute liver injury in mice. Microb Pathog. 2018 Dec;125:418–422.
   PubMed Web of Science ®Google Scholar
• Wu W, Yu T, Wu Y, et al. The miR155HG/miR-185/ANXA2 loop contributes to glioblastoma growth and progression. J Exp Clin Cancer Res. 2019 Mar 21;38(1):133.
   PubMedGoogle Scholar
• Bai TL, Liu YB, Li BH. MiR-411 inhibits gastric cancer proliferation and migration through targeting SETD6. Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3344–3350.
   PubMed Web of Science ®Google Scholar
• Gao X, Ge J, Li W, et al. Over-expression of miR-411-5p and miR-434-3p promotes the osteoblast differentiation by targeting GATA4. Mol Cell Endocrinol. 2020;506:110759.
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu T, Jin H, et al. MiR-411 suppresses the development of bladder cancer by regulating ZnT1. Onco Targets Ther. 2018;11:8695–8704.
   PubMed Web of Science ®Google Scholar
• Skalsky RL, Cullen BR. Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene. PLoS One. 2011;6(9):e24248.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang M, Cheng J, et al. MiR-411 functions as a tumor suppressor in renal cell cancer. Int J Biol Markers. 2017 Oct 31;32(4):e454–e460.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu G, Liu G, et al. miR-411-5p inhibits proliferation and metastasis of breast cancer cell via targeting GRB2. Biochem Biophys Res Commun. 2016 Aug 5;476(4):607–613.
   PubMed Web of Science ®Google Scholar
• Wang SY, Li Y, Jiang YS, et al. Investigation of serum miR-411 as a diagnosis and prognosis biomarker for non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2017 Sep;21(18):4092–4097.
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang H, Liu X, et al. Oncogenic microRNA-411 promotes lung carcinogenesis by directly targeting suppressor genes SPRY4 and TXNIP. Oncogene. 2019 Mar;38(11):1892–1904.
   PubMed Web of Science ®Google Scholar
• Bhargava S, Patil V, Mahalingam K, et al. Elucidation of the genetic and epigenetic landscape alterations in RNA binding proteins in glioblastoma. Oncotarget. 2017 Mar 7;8(10):16650–16668.
   PubMedGoogle Scholar
• Guo L, Yuan J, Xie N, et al. miRNA-411 acts as a potential tumor suppressor miRNA via the downregulation of specificity protein 1 in breast cancer. Mol Med Rep. 2016 Oct;14(4):2975–2982.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Rao X, Huang X, Zhou Z, et al. An improvement of the 2^(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinforma Biomath. 2013 Aug;3(3):71–85.
   PubMedGoogle Scholar
• Clement T, Salone V, Rederstorff M. Dual luciferase gene reporter assays to study miRNA function. Methods Mol Biol. 2015;1296:187–198.
   PubMedGoogle Scholar
• Yin J, Zeng A, Zhang Z, et al. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma. EBioMedicine. 2019 Apr;42:238–251.
   PubMed Web of Science ®Google Scholar
• Hou WZ, Chen XL, Qin LS, et al. MiR-449b-5p inhibits human glioblastoma cell proliferation by inactivating WNT2B/Wnt/beta-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 2020 May;24(10):5549–5557.
   PubMed Web of Science ®Google Scholar
• Stark AM, Stepper W, Mehdorn HM. Outcome evaluation in glioblastoma patients using different ranking scores: KPS, GOS, mRS and MRC. Eur J Cancer Care (Engl). 2010 Jan 1;19(1):39–44.
   PubMed Web of Science ®Google Scholar
• Sacko A, Hou MM, Temgoua M, et al. Evolution of the Karnofsky Performance Status throughout life in glioblastoma patients. J Neurooncol. 2015 May;122(3):567–573.
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009 Feb 19;360(8):765–773.
   PubMed Web of Science ®Google Scholar
• Xia K, Zhang Y, Cao S, et al. miR-411 regulated ITCH expression and promoted cell proliferation in human hepatocellular carcinoma cells. Biomed Pharmacother. 2015 Mar;70:158–163.
   PubMed Web of Science ®Google Scholar
• Li Y, Ge YZ, Xu L, et al. Circular RNA ITCH: a novel tumor suppressor in multiple cancers. Life Sci. 2020;254:117176.
   PubMed Web of Science ®Google Scholar
• Huang T, Chen Y, Zeng Y, et al. Long non-coding RNA PSMA3-AS1 promotes glioma progression through modulating the miR-411-3p/HOXA10 pathway. BMC Cancer. 2021 Jul 22;21(1):844.
   PubMed Web of Science ®Google Scholar
• Deguchi S, Katsushima K, Hatanaka A, et al. Oncogenic effects of evolutionarily conserved noncoding RNA ECONEXIN on gliomagenesis. Oncogene. 2017 Aug 10;36(32):4629–4640.
   PubMed Web of Science ®Google Scholar
• Shan D, Shang Y, Hu T. MicroRNA-411 inhibits cervical cancer progression by directly targeting STAT3. Oncol Res. 2019 Feb 21;27(3):349–358.
   PubMed Web of Science ®Google Scholar
• Han D, Yu T, Dong N, et al. Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells. J Exp Clin Cancer Res. 2019 Jul 5;38(1):289.
   PubMed Web of Science ®Google Scholar
• Kim BH, Lee H, Park CG, et al. STAT3 inhibitor ODZ10117 suppresses glioblastoma malignancy and prolongs survival in a glioblastoma xenograft model. Cells. 2020 15;9(3):Mar.
   Web of Science ®Google Scholar
• Piperi C, Papavassiliou KA, Papavassiliou AG. Pivotal role of STAT3 in shaping glioblastoma immune microenvironment. Cells. 2019 6;8(11):Nov.
   Web of Science ®Google Scholar